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Mammalian cells are restricted from proliferating indefinitely. Telomeres at the end of each
chromosome are shortened at cell division and, when they reach a critical length, the cell will enter
permanent cell cycle arrest - a state known as senescence. This mechanism is thought to be tumor
suppressing, as it helps prevent precancerous cells from dividing uncontrollably.
Stem cells express the enzyme telomerase, which elongates the telomeres, thereby postponing
senescence. However, unlike germ cells and most types of cancer cells, stem cells only express
telomerase at levels insufficient to fully maintain the length of their telomeres leading to a slow
decline in proliferation potential. It is not yet fully understood how this decline influences the risk
of cancer and the longevity of the organism.
We here develop a stochastic model to explore the role of telomere dynamics in relation to both
senescence and cancer. The model describes the accumulation of cancerous mutations in a multicel-
lular organism and creates a coherent theoretical framework for interpreting the results of several
recent experiments on telomerase regulation.
We demonstrate that the longest average cancer free life span before cancer onset is obtained when
stem cells start with relatively long telomeres that are shortened at a steady rate at cell division.
Furthermore, the risk of cancer early in life can be reduced by having a short initial telomere length.
Finally, our model suggests that evolution will favour a shorter than optimal average cancer free
life span in order to postpone cancer onset until late in life.
PACS numbers: 87.10.Mn, 87.19.xj, 82.39.Rt
INTRODUCTION
Telomeres are the non-coding ends of chromosomes
that prevent loss of genomic information during chromo-
some replication [1]. Each cell division leads to a telom-
ere shortening of 50-100 base pairs, partly due to what is
known as the end-replication problem [2, 3]. When the
telomeres reach a critical length the cell goes senescent, a
state of permanent replication arrest that prohibits any
further proliferation [4]. The number of divisions a cell
can undergo before it reaches senescence is called the
Hayflick limit [5].
Short telomeres have been linked to increased mor-
tality and age related diseases [6] and accumulation of
senescent cells is seen as one of the major causes of age-
ing [5, 7, 8]. However, the proliferation limit associated
with telomere attrition is thought to work as a fail-safe
mechanism against cells that divide in an uncontrolled
and rapid fashion, particularly cancer cells [9].
Genes that are critical in maintaining cells in a non-
cancerous state are called proto-oncogenes or tumor sup-
pressor genes. Estimates of the number of mutations in
these genes needed for a healthy cell to turn cancerous
range from 3-6 [10] and above [11].
Cancer cells replicate uncontrollably and have unlim-
ited proliferation capability, known as cellular immor-
tality [12]. Consequently, the cancerous cell must by-
pass the end-replication problem, which in 90% of can-
cers is done by expressing the enzyme telomerase [13].
Telomerase, which mainly consists of the two components
TERT and TERC, elongates the telomeres such that the
telomere length of cancer cells is maintained during repli-
cation [14]. Besides being present in cancer cells, telom-
erase is also found in stem cells and germ line cells [12].
The amount of telomerase in germ line cells is sufficient
to maintain telomere length [1]. For stem cells, however,
the level of telomerase is so low that telomeres are still
shortened after each cell division, but at a lower rate than
for somatic cells [15].
It is an open question why stem cells express telom-
erase, and why the level of telomerase is not high enough
to avoid a shortening of the telomere length throughout
life.
It has been suggested that telomere shortening is
a trade-off between limiting oncogenesis and reducing
physiological ageing [16–18].
The capability of cells to tune their telomere shorten-
ing rate by varying the expression of telomerase suggests
the possibility of optimal telomere shortening strategies.
In this paper we present a stochasticl model that anal-
yses how shortening of stem cell telomeres are coupled to
the trade-off between ageing and postponing cancer. Pre-
vious mathematical models for telomere dynamics have
mostly focused on the cellular transition to a senescent
state [19, 20], and previous cancer models have focused
mostly on oncogenesis [21, 22]. This work tries to bridge
these areas of focus, developing a more coherent math-
ematical modelling framework for considering telomere
dynamics in relation to both senescence and cancer. We
find that there exists a telomere shortening rate that op-
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2timizes the cancer free life span of the organism. Our
results also show that a suboptimal cancer free life span
strategy may be selected in order to reduce the risk of
cancer before the childbearing age.
THE MODEL
The stochatic model describes the accumulation of can-
cerous mutations in a multicellular organism, where each
cell division will result in a shortening of the telomere
sequence due to the end-replication-problem.
Mutations can arise during division of either somatic
cells or stem cells. Initially an unmutated stem cell di-
vides, thereby creating a somatic cell and a daughter
stem cell. The somatic cell then proliferates until it, af-
ter H0 divisions, reaches the Hayflick limit and undergoes
senescence.
The Hayflick limit can be interpreted as the conversion
of an initial telomere length, since a correlation between
the replicative capacity of a cell and its initial telomere
length has been shown [23].
During each division, the somatic cell has a probability
p of acquiring a cancerous mutation, which is then prop-
agated through the cell lineage in our model. In order
to maintain homeostasis, only one daughter cell survives
after each replication.
When the somatic cell has gone senescent it is removed
and all mutations accumulated in the somatic cell lineage
are lost.
The daughter stem cell then divides to produce a new
daughter stem cell and a new generation of somatic cells.
Each time a stem cell divides, the Hayflick limit HG
is reduced by a constant amount α > 0, corresponding
to the daughter stem cell having shorter telomeres than
its parent. Additionally, there is a probability psc of a
cancerous mutation occurring in the self-renewing stem
cell. Such mutations are permanent and are inherited by
all stem cells in the stem cell lineage in the model.
If at any point the cell accumulates more than Cm mu-
tations, the organism is no longer cancer free. This will
inevitably happen as mutations are steadily accumulated
in the stem cell lineage, such that somatic cell lines start
with more and more mutations.
The total number of cell divisions that the system un-
dergoes before the onset of cancer is interpreted as the
cancer free life span of the organism. A schematic illus-
tration of the model is shown in Fig. 1.
THEORETICAL ANALYSIS
In this section we derive a mathematical expression for
the average cancer free life span obtained for different
telomere shortening strategies.
Divisions
Stem cell generations
HG
−α
H0
3 mutations
2 mutations
1 mutation
0 mutations
Stem Cell
Figure 1: Schematic illustration of the model. The flow of
time follows the dashed arrows. Initially, a stem cell divides.
One daughter cell specializes into a somatic cell, which pro-
liferates until it reaches the Hayflick limit and goes senescent
(first vertical row). The daughter stem cell then divides to
produce a new daughter stem cell and a new generation of
somatic cells (subsequent vertical rows). For each genera-
tion the Hayflick limit HG is reduced by a constant amount
α. At every cell division, somatic cells and stem cells have
the probabilities p and psc, respectively, to acquire cancer-
ous mutations. Mutations in stem cells are permanent, while
mutations in somatic cell lineages are lost when the cell line
reaches the Hayflick limit. When the system has accumulated
more than Cm mutations (which in this illustration is 2), the
organism will have developed cancer. The total cancer free
life span is thus the sum of all somatic divisions.
Each time a stem cell is introduced to the tissue, the
Hayflick limit is reduced from its initial value H0 due to
the telomere shortening of the stem cell. After G gener-
ations the Hayflick limit HG is given by
HG = bH0 − αGe (1)
where be denotes rounding to the nearest integer. Dur-
ing each of the subsequent HG cell divisions, the cells
have a probability p of acquiring a cancerous mutation.
The probability F (x) that the cell line acquires x or fewer
mutations before it reaches the Hayflick limit is given by
the Binomial cumulative distribution function
F (x) =
x∑
i=0
(
HG
i
)
pi(1− p)HG−i. (2)
At each stem cell division there is a risk psc of acquir-
ing a permanent mutation in the stem cell lineage. The
probability for the organism to have j mutations in the
stem cells after G generations, but still be cancer free, is
denoted SG,j . This is given by the recurrence relation
SG+1,j =
(
SG,j(1− psc) + SG,j−1psc
)
F (Cm − j), (3)
where the expression in the bracket is the probability
of having j mutations in the stem cell, and F (Cm − j)
3is the probability of not exceeding the critical number
of Cm mutations during the somatic divisions, thereby
developing cancer.
The initial stem cell is unmutated, S0,0 = 1, so in terms
of Kroeniker-delta the starting condition is
S0,j = δ0j (4)
Using Eq. (3) and Eq. (4), the system can be solved
numerically. Notice that when α > 0, the Hayflick limit
will eventually drop to zero, after which the stem cell
undergoes senescence even if the cell line is still cancer
free. According to Eq. (1) this will happen after H0−0.5α
generations, which therefore gives an upper bound for
the total cancer free life span of the organism.
The overall probability that the organism will not have
developed cancer at a given generation is defined as.
SG =
{∑
j SG,j for G ≤ H0−0.5α
0 for G > H0−0.5α
(5)
The average cancer free life span 〈L(H0, α)〉 is the
mean number of cell divisions the organism will live be-
fore exceeding the critical number of mutations. It can
be found by multiplying the probability of getting cancer
at each generation (SG−SG+1) by the number of cancer
free generations and the average Hayflick limit each of
these consisted of.
〈L(H0, α)〉 =
∞∑
G=1
(SG − SG+1)GH0 +HG
2
(6)
When α = 0 the Hayflick limit H0 is constant and Eq.
(6) becomes
〈L(H0, 0)〉 = H0
∞∑
G=1
SG (7)
Note that for this case SG will never reach 0 and a cut
off is necessary. This is made when SG < 10
−5 and has
negligible influence on the cancer free life span.
RESULTS
We now fix the ratio between the mutation probabili-
ties such that ppsc = 100 according to [24, 25], and set p
= 10−2 and Cm = 6.
These choices of parameter values are not essential for
the conclusions and other choices yield qualitatively sim-
ilar results (see supplementary material).
The average cancer free life span is calculated from
Eq. (6) and Eq. (7) and their performance compared to
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Figure 2: Deviation in average cancer free life span for dif-
ferent initial Hayflick limits and shortening factors α com-
pared to the longest possible cancer free life span for constant
Hayflick limit (strategy 1). The overall longest cancer free
life span (strategy 2) is obtained for a higher initial Hayflick
limit, which is then slowly reduced through telomere short-
ening in stem cells. Strategy 3 has the same initial Hayflick
limit as strategy 1 and the same telomere shortening rate as
strategy 3. Black arrows show how different experimental
setups can change the position in parameter space through
modifications of the initial Hayflick limit of stem cells and
the telomere shortening rate. A low initial Hayflick limit and
high telomere shortening rate cause premature ageing due to
increased accumulation of senescent cells. Parameters: Cm =
6, p = 10−2, psc = 10−4.
the strategy with no stem cell telomere shortening that
yields the longest cancer free life span, as obtained from
Eq. (7). The result is shown in Fig. 2, where three
strategies for further study are labeled in the following
way:
1. The strategy where stem cells express a telomerase
activity, such that the telomere length of stem cells
is constant over time (α = 0). The initial Hayflick
limit is chosen such that the cancer free life span is
maximized.
2. The strategy that gives the longest cancer free life
span when allowing stem cell telomeres to shorten
at each division (α > 0). Again, the initial Hayflick
limit is chosen such that the cancer free life span is
maximized. This results in a larger initial Hayflick
limit than for strategy 1.
3. The strategy that combines the initial Hayflick
limit from strategy 1 and the stem cell telomere
shortening rate from strategy 2. Note that this
strategy yields similar cancer free life span as ob-
tained for strategy 1.
4The shorter the telomere length of stem cells is, the
more frequent is the need for self renewal in order to
maintain homeostasis in the tissue. Every self renewal is
accompanied with the risk of accumulating an additional
permanent mutation [25]. Therefore, a lower value for
H0 increases the rate at which mutations occur in the
stem cells.
Furthermore, a shorter H0 will reduce the amount of
cell divisions before stem cell senescence, resulting in
faster ageing and a shorter maximum cancer free life
span.
Keeping H0 fixed and down-regulating the telomerase
production is equivalent to increasing α, thus moving up-
wards in Fig. 2. The higher α will suppress the risk of
developing cancer, as the risk can be managed by un-
dergoing fewer divisions before senescence. The higher
turnover rate results in systems where cancer is rarely
developed, but where the cancer free life span of other-
wise healthy cell lineages is limited by stem cells going
senescent.
Up-regulation of telomerase in stem cells results in a
lower α while up-regulation of telomerase in somatic cells
will increase the proliferation potential, which is equiv-
alent to a higher H0. These two effects combined can,
therefore, in Fig. 2 be illustrated as a shift downwards
to the right.
This shift of strategy can in small quantities be ad-
vantageous and prolong life, but is also associated with
an increased risk of developing cancer since somatic cells
are able to continue proliferating for longer before the
senescent fail-safe mechanism sets in.
These observation are supported by Fig. 3a and 3b,
which show the probability of the organism to still be
cancer free as a function of time, for each of the strategies
1, 2, and 3.
Surprisingly, we see that strategy 2, which yields the
longest cancer free life span, is also the one that is most
exposed to cancer early in life. This strategy benefits
from less stem cells attrition late in life, thereby supply-
ing the system with less mutated cells, which in the end
increases the average time before cancer development.
Minimizing the risk of developing cancer at an early age
can be done by lowering H0, raising α, or both. With
strategy 3 a higher percentage of a population would
therefore still be a cancer free in the early in life com-
pared to other strategies as 1 and 2 that have similar or
longer cancer free life span.
These results indicate that evolution would favour
species with a restricted telomerase production in their
stem cells above species that maintain their stem cells
telomere length fully throughout life. This shortening
rate can then be adjusted such that a lower cancer risk is
obtained at the childbearing age, thereby increasing the
chance of giving birth.
Therefore, strategies that solely optimize cancer free
life span may not be advantageous from an evolutionary
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Figure 3: Probability of not yet having developed cancer as a
function of time for different telomere shortening strategies.
A: For all three strategies, the probability slowly decreases
with time. Only very few individuals will develop cancer later
than twice the mean cancer free life span of the population.
B: Probability of not yet having developed cancer for strategy
2 and 3 compared to strategy 1. Strategy 2, which has the
longest average cancer free life span, will have a higher prob-
ability of cancer development early in life. Strategy 3, which
has a low initial Hayflick limit, is able to postpone cancer
until later in life.
point of view, if they increase the risk of cancer early in
life when reproduction takes place, as seen with strat-
egy 2. We also find that cancer free life span for some
strategies, e.g. Strategy 3, can be prolonged even further
if telomerase is up-regulated at a later stage in life (see
supplementary materials).
Strategy 3 and other stem cell shortening strategies are
not without downsides, as the somatic cells will undergo
senescence after fewer and fewer divisions. Shorter telom-
eres and an accumulation of senescent cells are closely re-
lated to biological ageing [26, 27], hence, strategies that
suppresses cancer early in life by shortening their telom-
eres are associated with accelerated aging.
DISCUSSION AND CONCLUSION
In our model a decrease of telomerase activity (TERT
or TERC) leads to a faster shortening of stem cell telom-
5eres per cell division. Our model predicts that any reduc-
tion of telomerase activity decreases the risk of cancers
early in life, but at the same time causes a higher rate
of stem cell replications. The increased replication rate
leads to an increased rate of cancerous mutations in the
stem cells. For certain regimes the advantages of telom-
erase activity down regulation resulting in a low risk of
cancer early in life is outweighed by the higher risk of
cancer later in life, and therefore the total cancer free
life span of the organism is reduced. The increased can-
cer risk when telomerase is removed was observed in a
study by Gonzlez et al. (2000) , where they found a
slight increase in oncogenesis in highly proliferating tis-
sue for TERC deficient mice[28]. In addition our model
also predicts that stem cells will go senescent faster, and
therefore cause faster ageing. This is also consistent with
experimental observations; in a TERC mouse study Liu
et al. (1998) found that a lack of telomerase caused the
mice to present premature ageing symptoms, especially
in highly proliferating tissue [29].
Our model demonstrates that telomerase up-
regulation, in general, leads to an organism more
prone to developing cancer, which was observed
experimentally by Gonzlez et al. (2002)[30].
Furthermore, the model predicts that a temporal in-
duction of telomerase could increase cancer free life span
(see Supplementary). If the organism starts with a mod-
erate telomerase activity and then increases the activity,
the organism could prevent cancer onset at an early stage
of life and postpone ageing, thereby increasing longevity.
A recent study by Bernandes de Jesus et al. (2012) sup-
ports this result. By inducing telomerase activity in adult
mice, they were able to increase longevity without in-
creasing the risk of cancer [31].
Additionally, it has been shown that, when comparing
two types of TERC deficient mice with different genetic
backgrounds - one type with initially shorter telomeres
and one with normal initial telomere length - the mice
with shorter telomeres show decreased viability, not due
to cancer, but due to premature ageing [32, 33]. Our
model demonstrates that decreasing H0 leads to a faster
attrition of the stem cell pool and therefore faster ageing.
In conclusion, our model offers an explanation to why
stem cells express telomerase at a moderate level, such
that their telomere lengths are not conserved but is short-
ened at a lower rate than in somatic cells. Furthermore,
our results suggest that, in stem cells, evolution will favor
short initial telomeres that are slowly shortened at each
division (strategy 3), as this strategy is able to reduce
the likelihood of cancer early in life.
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7– SUPPLEMENTARY MATERIAL –
In this supplementary note, we show that the choices of the parameter values Cm, p and psc are not essential for
the overall conclusions drawn in the article regarding cancer free life span obtained by shortening the Hayflick limit
after each stem cell division.
We here present three cases where the value of one parameter is varied, compared to those used for generating
figure 2 in the article, while the two others kept constant. We show again, that some shortening strategies can both
prolong life and postpone cancer early in life, and that the benefits of this depends on the choice of parameter values.
The black dot on the figures represents the strategy with a constant Hayflick limit that produces the longest cancer
free life span. First we keep p and psc fixed and change Cm to 4. See figure 4
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Figure 4: Deviation in average cancer free life span for different initial Hayflick limits and shortening factors α compared to the
longest possible cancer free life span for constant Hayflick limit (black dot). Decreasing Cm reduces the benefit one can obtain
by shortening the stem cell telomeres in order to maximize the cancer free life span compared to the strategy with constant
Hayflick limit. Parameters: Cm = 4, p = 10
−2 and psc = 10−4.
8Second, the stem cell mutation rate psc is increased by a factor 10, with Cm and p kept fixed. See figure 5
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Figure 5: Keeping Cm and p fixed, but increasing psc by a factor 10, results in optimal strategies with higher H0 and α as
stem cells should be introduced less frequent due to their increased mutation probability. Parameters: Cm = 6, p = 10
−2 and
psc = 10
−3.
9Lastly, the mutation rate for somatic cells p is increased by a factor 2, with Cm and psc kept unchanged. See figure
6
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Figure 6: Increasing the mutations rate for somatic cells will shift the optimal strategies towards lower H0 and α as stem cells
should now be introduced more frequently. Parameters: Cm = 6, p = 2 · 10−2 and psc = 10−4.
10
In order to verify that life can be prolonged by adding telomerase later in life, we here present one example of how
this could occur. In this example we compare strategy 3 with strategy 3*. Strategy 3* has the same initial conditions
as strategy 3, but will, when reaching HG = 39, double its telomerase production (halving α) for the remaining cancer
free life span. With this up-regulation in telomerase production the longevity can be increased. The increased cancer
free life span relies solely on the ability to postpone stem cell senescence by stimulating it with telomerase. The steep
peak in Fig. (7), which is seen after a time 2.1 longer than the mean cancer free life span, is caused by the stem cells
of strategy 3 going senescent so SG immediately drops to 0.
0 0.5 1 1.5 2 2.5 3
0
0.02
0.04 Strategy 3* − Strategy 3
Telomerase up regulation
Pr
ob
ab
ili
ty
 to
 b
e 
ca
nc
er
 fr
ee
 
co
m
pa
re
d 
to
 st
ra
te
gy
 3
Fraction of mean cancer free life span of strategy 3
Figure 7: Increased probability to be cancer free for two strategies with same initial conditions but with strategy 3* having an
up-regulation of telomerase later in life. The up-regulation (lower α) leads to slightly increased cancer risk, but the strategy
turns advantageous later on, as the increased telomerase production postpones the time at which the stem cells go senescent.
The stem cells of strategy 3 go senescent shortly after a time 2.1 longer than the mean cancer free life span, whereas this is
postponed for strategy 3*.
